Subacute cutaneous lupus erythematosus induced or exacerbated by proton pump inhibitors [16]

Acta Dermato-Venereologica

Volumn 88, Issue 1, 2008, Pages 87-89

  Dam, Claus ^a   Bygum, Anette ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; HYDROCORTISONE; HYDROQUININE; LANSOPRAZOLE; PANTOPRAZOLE; PREDNISOLONE; STEROID;

ADDISON DISEASE; ADULT; CASE REPORT; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DUODENUM ULCER; ESOPHAGITIS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LABORATORY TEST; LETTER; MALE; PRIORITY JOURNAL; RASH; SKIN BIOPSY; SKIN LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AUTOANTIBODIES; DUODENAL ULCER; ESOPHAGITIS; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, CUTANEOUS; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMP INHIBITORS; SKIN;

EID: 38949189308     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0335     Document Type: Letter

References (15)

1. Reilly JP. Safety profile of the proton-pump inhibitors. Am J Health-Syst Pharm 1999; 56 Suppl 4: S11-17.
2. Raison-Peyron N, Minh HB, Peyron JL, Demoly P, Guillot B. Toxidermie photodistribuée induite par les inhibiteurs de la pompe à protons. Thérapie 2005; 60: 85-87.
3. Bracke A, Nijsten T, Vandermaesen J, Meuleman L, Lambert J. Lansoprazole-induced subacute cutaneous lupus erythematosus: two cases. Acta Derm Venereol 2005; 85: 353-354.
4. Kuhn A, Gensch K, Stander S, Bonsmann G. Cutaneous lupus erythematosus. Part 1: clinical manifestations and classification. Hautarzt 2006; 57: 251-268.
5. Sontheimer RD. Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings. Autoimmun Rev 2005; 4: 253-263.
6. Crowson AN, Magro C. The cutaneous pathology of lupus erythematosus: a review. J Cutan Pathol 2001; 28: 1-23.
7. Parodi A, Caproni M, Cardinali C, Bernacchi E, Fuligni A, De Panfilis G, et al. Clinical, histological and immunopathological features of 58 patients with subacute cutaneous lupus erythematosus. A review by the Italian group of immunodermatology. Dermatology 2000; 200: 6-10.
8. Reed BR, Huff JC, Jones SK, Orton PW, Lee LA, Norris DA. Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy. Ann Intern Med 1985; 103: 49-51.
9. Srivastava M, Rencic A, Diglio G, Santana H, Bonitz P, Watson R, et al. Drug-induced Ro/SSA-positive cutaneous lupus erythematosus. Arch Dermatol 2003; 139: 45-49.
10. Antonov D, Kazandjieva J, Etugov D, Gospodinov D, Tsankov N. Drug-induced lupus erythematosus. Clin Dermatol 2004; 22: 157-166.
11. Rowell NR, Beck JS, Anderson JR. Lupus Erythematosus and erythema multiforme-like lesions. A syndrome with characteristic immunological abnormalities. Arch Dermatol 1963; 88: 176-180.
12. Massone C, Parodi A, Rebora A. Erythema multiforme-like subacute cutaneous lupus erythematosus: a new variety? Acta Derm Venereol 2000; 80: 308-309.
13. Bonsmann G, Schiller M, Luger TA, Stander S. Terbinafine-induced subacute cutaneous lupus erythematosus. J Am Acad Dermatol 2001; 44: 925-931.
14. Callen JP. Cutaneous lupus erythematosus: a personal approach to management. Australas J Dermatol 2006; 47: 13-27.
15. Cockayne SE, Glet RJ, Gawkrodger DJ, McDonagh AJ. Severe erythrodermic reactions to the proton pump inhibitors omeprazole and lansoprazole. Br J Dermatol 1999; 141: 173-175.